Last reviewed · How we verify
NAH therapy
NAH therapy, marketed by Bayer, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and revenue generation, though specific figures are not provided. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | NAH therapy |
|---|---|
| Also known as | Second novel anti-hormonal therapy |
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) (PHASE4)
- An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings
- Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NAH therapy CI brief — competitive landscape report
- NAH therapy updates RSS · CI watch RSS
- Bayer portfolio CI